ClinicalTrials.gg
CompletedNCT03150719Updated Sep 12, 2019Results posted

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

A Phase 3 interventional study of Tezacaftor/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 53 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
23rd of 43
98 · median 100
Started
2017
with 2 others
Phase 3
25 of 43
none open now
Registered
14th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 23rd largest by enrollment, is one of 3 that started in 2017, is one of 25 in phase 3, and was the 14th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

Study VX16-661-114 (Study 114) is a Phase 3b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are homozygous for the F508del mutation on the cystic fibrosis transmembrane conductance regulator gene (CFTR) gene and who discontinued treatment with Orkambi due to respiratory symptoms considered related to treatment. This study is designed to evaluate the safety and efficacy of Tezacaftor/Ivacaftor (TEZ/IVA).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, guidelines, and other study procedures.
  • Prior discontinuation of Orkambi, with at least 1 respiratory sign or symptom considered related to therapy.
  • Resolution or stabilization of qualifying event(s) >28 days prior to Screening.
  • Discontinuation of Orkambi therapy must have occurred within approximately 12 weeks from the first dose of Orkambi.
  • Homozygous for F508del mutation in the CFTR gene as documented in the subject's medical record. If genotype documentation is not available in the medical record, genotyping will be performed during screening.
  • ≥25% and ≤90% of predicted normal for age, sex, and height.
  • Stable CF disease as judged by the investigator.
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Recent rapid or progressive deterioration in respiratory status.
  • Receiving continuous oxygen at >2L/min or on face-mask ventilation.
  • Any protocol-defined exclusionary laboratory values at Screening.
  • Class B or C hepatic impairment.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or change in therapy for pulmonary disease within 28 days before Day 1.
  • Documentation of colonization with organisms associated with a more rapid decline in pulmonary status.
  • History of lung transplantation since most recent initiation of Orkambi.
  • History of alcohol or drug abuse in the past year as deemed by the investigator.
  • Participation in an drug study or use of a CFTR modulator within 28 days or 5 terminal half-lives of the investigational drug or modulator (whichever is longer).
  • Use of restricted medications or foods within the specified window before the first dose of study drug, or an anticipated need or use of restricted medication or foods after the first dose of study drug.
  • Pregnant or nursing females: Females of must have a negative pregnancy test at Screening and Day 1.
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.

    Drug: Placebo

  • Experimental
    TEZ/IVA

    Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.

    Drug: Tezacaftor/Ivacaftor · Drug: Ivacaftor

Interventions

  • DrugTezacaftor/Ivacaftor

    Drug pages: Tezacaftor · Ivacaftor

    TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.

    Also known as: TEZ/IVA; VX-661/VX-770

  • IVA 150 mg tablet.

    Also known as: VX-770; IVA

  • DrugPlacebo

    Placebo matched to TEZ/IVA fixed-dose combination tablet.

  • DrugPlacebo

    Placebo matched to IVA tablet.

06

What researchers measure

Primary outcomes

  1. Incidence of Respiratory Adverse Events of Special Interest (RAESIs)

    RAESIs included chest discomfort, dyspnea (shortness of breath), respiration abnormal (chest tightness), asthma, bronchial hyperreactivity, bronchospasm, and wheezing.

    Time frame: Day 1 up to Day 84

Secondary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 28 and Day 56

  2. Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 28 and Day 56

  3. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Day 28 and Day 56

  4. Tolerability as Assessed by Number of Participants Who Discontinued Treatment

    Time frame: Day 1 through Day 56

  5. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 84

07

Results

Posted Sep 12, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboTEZ/IVA
Started4750
Completed4648
Not completed12
Withdrew: Adverse event01
Withdrew: Death01
Withdrew: Other10

Outcome measures

PrimaryIncidence of Respiratory Adverse Events of Special Interest (RAESIs)

RAESIs included chest discomfort, dyspnea (shortness of breath), respiration abnormal (chest tightness), asthma, bronchial hyperreactivity, bronchospasm, and wheezing.

Time frame:
Day 1 up to Day 84
Reported as:
Count of participants · Participants
Incidence of Respiratory Adverse Events of Special Interest (RAESIs)
ParticipantsPlaceboTEZ/IVA
Incidence of Respiratory Adverse Events of Special Interest (RAESIs)107
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 28 and Day 56
Reported as:
Mean · percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements
percent predicted of FEV1PlaceboTEZ/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements-0.6 ± 3.42.2 ± 4.8
Statistical analysis
  • Placebo vs TEZ/IVA · Mean difference: 2.7 · 95% CI 1.0 to 4.4
SecondaryRelative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 28 and Day 56
Reported as:
Mean · percent change
Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements
percent changePlaceboTEZ/IVA
Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements-1.5 ± 8.15.2 ± 12.0
Statistical analysis
  • Placebo vs TEZ/IVA · Mean difference: 6.7 · 95% CI 2.5 to 10.9
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Day 28 and Day 56
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements
units on a scalePlaceboTEZ/IVA
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements4.7 ± 15.45.7 ± 14.2
Statistical analysis
  • Placebo vs TEZ/IVA · Mean difference: 1.1 · 95% CI -4.9 to 7.0
SecondaryTolerability as Assessed by Number of Participants Who Discontinued Treatment
Time frame:
Day 1 through Day 56
Reported as:
Count of participants · Participants
Tolerability as Assessed by Number of Participants Who Discontinued Treatment
ParticipantsPlaceboTEZ/IVA
Tolerability as Assessed by Number of Participants Who Discontinued Treatment22
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 84
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboTEZ/IVA
Participants with AEs3937
Participants with SAEs95

Adverse events

Collected over Day 1 up to Day 84. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/47 (0%)9/47 (19.1%)28/47 (59.6%)
TEZ/IVA1/50 (2%)5/50 (10%)30/50 (60%)
Most frequent serious events
Most frequent serious events
EventPlaceboTEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations7/473/50
Lower respiratory tract infectionInfections and infestations1/470/50
Pericardial effusionCardiac disorders1/470/50
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/470/50
Pleuritic painRespiratory, thoracic and mediastinal disorders1/470/50
SepsisInfections and infestations0/471/50
ConstipationGastrointestinal disorders0/471/50
Multiple organ dysfunction syndromeGeneral disorders0/471/50
Suicidal ideationPsychiatric disorders0/471/50
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboTEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations9/474/50
CoughRespiratory, thoracic and mediastinal disorders8/479/50
HeadacheNervous system disorders7/476/50
NasopharyngitisInfections and infestations0/476/50
DyspnoeaRespiratory, thoracic and mediastinal disorders5/475/50
Sputum increasedRespiratory, thoracic and mediastinal disorders5/472/50
Abdominal pain upperGastrointestinal disorders5/474/50
FatigueGeneral disorders4/472/50
ConstipationGastrointestinal disorders0/474/50
NauseaGastrointestinal disorders2/474/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTEZ/IVATotal
Mean33.3 ± 10.034.3 ± 8.733.8 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTEZ/IVATotal
Female303161
Male171936
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTEZ/IVATotal
Hispanic or Latino314
Not Hispanic or Latino404181
Unknown or Not Reported4812
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTEZ/IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White424284
More than one race000
Unknown or Not Reported4812
08

Study locations

53 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • UCSF - Fresno, Community Regional Medical Center
    Fresno, California 93701, United States
  • Miller Children's Hospital / Long Beach Memorial
    Long Beach, California 90806, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Arnold Palmer Hospital
    Orlando, Florida 32806, United States
  • Tampa General Hospital Cardiac and Lung Transplant Clinic
    Tampa, Florida 33606, United States
  • Children's Speciality Services at North Druid Hills
    Atlanta, Georgia 30324, United States
  • St. Luke's CF Center of Idaho
    Boise, Idaho 83702, United States
  • Advocate Children's Hospital - Park Ridge / North Suburban Pulmonary and Critical Care Consultants
    Niles, Illinois 60714, United States
  • Southern Illinois University
    Springfield, Illinois 62702, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • The University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kentucky Clinic
    Lexington, Kentucky 40536, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Hospital Cystic Fibrosis Center
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Mount Sinai Beth Israel
    New York, New York 10003, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Santiago Reyes, M.D.
    Oklahoma City, Oklahoma 73112, United States
  • Drexel University College of Medicine/ Drexel Adult Cystic Fibrosis Center
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Tennessee Medical Center
    Nashville, Tennessee 37920, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78207, United States
  • University of Utah / Primary Children's Medical Center
    Salt Lake City, Utah 84132, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Children's Hospital of Richmond at VCU, Children's Pavilion
    Richmond, Virginia 23298, United States
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, France
  • Centre Hospitalier Universitaire De Grenoble - Hopital Michallon
    Grenoble, France
  • CHU de Montpellier - Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, France
  • Centre Hospitalier Universitaire De Nantes
    Nantes, France
  • Centre hospitalier universitaire de Nice, Pulmonology
    Nice, France
  • Hopital Cochin
    Paris Cedex 14, France
  • Centre Hospitalier Universitaire - Hopitaux de Rouen
    Rouen, France
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen
    Essen, Germany
  • Klinikum Innenstadt, University of Munich
    Muenchen, Germany
  • Pneumologische Praxis Pasing
    Muenchen, Germany
  • Universitaetsklinikum Tuebingen Klinik fuer Kinder- und Jugendmedizin
    Tuebingen, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Aug 2018, 14 months.

Results were first posted in Sep 2019, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 14 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2017
First posted
May 12, 2017
StartActual
May 24, 2017
Primary completionActual
Aug 9, 2018
CompletionActual
Aug 9, 2018
Results first posted
Sep 12, 2019
Last update
Sep 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03150719
Responsible party
Sponsor
First posted
May 12, 2017
Start date
May 24, 2017
Primary completion
Aug 9, 2018
Completion
Aug 9, 2018
Results posted
Sep 12, 2019
Last update
Sep 12, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion